Cargando…

Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging

The objective of this study was to investigate in vitro the interactions between novel epidermal growth factor receptor kinase inhibitors (EGFRIs) developed for positron emission tomography (PET) imaging and the major eﬄux transporter breast cancer resistance protein (BCRP/ABCG2). Seven compounds we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qawasmi, Israa, Shmuel, Miriam, Eyal, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240039/ https://www.ncbi.nlm.nih.gov/pubmed/25484865 http://dx.doi.org/10.3389/fphar.2014.00257

Ejemplares similares

Expression of ABCG2 (BCRP) in mouse models with enhanced erythropoiesis
por: Latunde-Dada, Gladys O., et al.
Publicado: (2014)

Chicken xenobiotic receptor upregulates the BCRP/ABCG2 transporter
por: Xu, Ziyong, et al.
Publicado: (2022)

Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib
por: Lemos, C, et al.
Publicado: (2009)

Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
por: Zhang, Wei, et al.
Publicado: (2018)

BCRP/ABCG2 in the Placenta: Expression, Function and Regulation
por: Mao, Qingcheng
Publicado: (2008)

BCRP/ABCG2 in the Placenta: Expression, Function and Regulation
por: Mao, Qingcheng
Publicado: (2008)

Tetrahydroquinoline/4,5‐Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2)
por: Vesga, Luis C., et al.
Publicado: (2021)

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
por: Huang, Wei-Chien, et al.
Publicado: (2013)

Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp
por: Zhao, Tingting, et al.
Publicado: (2022)

Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2
por: Inoue, Yutaka, et al.
Publicado: (2019)

Effects of α-Adrenoceptor Antagonists on ABCG2/BCRP-Mediated Resistance and Transport
por: Takara, Kohji, et al.
Publicado: (2012)

Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma
por: Sukowati, Caecilia HC, et al.
Publicado: (2012)

New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies
por: Westover, David, et al.
Publicado: (2015)

ABCG2/BCRP transport mechanism revealed through kinetically excited targeted molecular dynamics simulations
por: Dudas, B., et al.
Publicado: (2022)

In Silico Prediction of Inhibition of Promiscuous Breast Cancer Resistance Protein (BCRP/ABCG2)
por: Ding, Yi-Lung, et al.
Publicado: (2014)

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines
por: Galetti, Maricla, et al.
Publicado: (2015)

Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2
por: Chen, Liming, et al.
Publicado: (2019)

Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics
por: Noguchi, Kohji, et al.
Publicado: (2014)

Pharmacogenetic Aspects of the Interaction of AT1 Receptor Antagonists With ATP-Binding Cassette Transporter ABCG2
por: Ripperger, Anne, et al.
Publicado: (2018)

Extra-Renal Elimination of Uric Acid via Intestinal Efflux Transporter BCRP/ABCG2
por: Hosomi, Atsushi, et al.
Publicado: (2012)

Modulating Drug Resistance by Targeting BCRP/ABCG2 Using Retrovirus-Mediated RNA Interference
por: Xie, Ni, et al.
Publicado: (2014)

The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications
por: Shraim, Bara A., et al.
Publicado: (2021)

Correction: Modulating Drug Resistance by Targeting BCRP/ABCG2 Using Retrovirus-Mediated RNA Interference
Publicado: (2014)

Genistein and Glyceollin Effects on ABCC2 (MRP2) and ABCG2 (BCRP) in Caco-2 Cells
por: Schexnayder, Chandler, et al.
Publicado: (2015)

Jump into a New Fold—A Homology Based Model for the ABCG2/BCRP Multidrug Transporter
por: László, Laura, et al.
Publicado: (2016)

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
por: Lemos, C, et al.
Publicado: (2008)

Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells
por: Chen, Yun-Ju, et al.
Publicado: (2011)

Breast cancer resistance protein (Bcrp/Abcg2) is selectively modulated by lipopolysaccharide (LPS) in the mouse yolk sac
por: Martinelli, L.M., et al.
Publicado: (2020)

Clinical Significance of ABCG2/BCRP Quantified by Fluorescent Nanoparticles in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Tada, Hiroshi, et al.
Publicado: (2023)

Modulation of Pathological Pain by Epidermal Growth Factor Receptor
por: Borges, Jazlyn P., et al.
Publicado: (2021)

Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications
por: Toyoda, Yu, et al.
Publicado: (2019)

OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance
por: Yang, Yuqi, et al.
Publicado: (2021)

Molecular Determinants of Glioblastoma Response to Epidermal Growth Factor Receptor Kinase Inhibitors
por: Komotar, Ricardo J., et al.
Publicado: (2008)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression
por: Nakanishi, Takeo, et al.
Publicado: (2012)

The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP
por: Ambjørner, Sophie E. B., et al.
Publicado: (2020)

The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells
por: Yin, Wang, et al.
Publicado: (2021)

Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis
por: Kong, Fanming, et al.
Publicado: (2021)

Teriflunomide Is an Indirect Human Constitutive Androstane Receptor (CAR) Activator Interacting With Epidermal Growth Factor (EGF) Signaling
por: Carazo, Alejandro, et al.
Publicado: (2018)

Baicalein Enhances the Oral Bioavailability and Hepatoprotective Effects of Silybin Through the Inhibition of Efflux Transporters BCRP and MRP2
por: Xu, Peng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8tlcaqandj507v52h32uh9bd28